Mayne is an emerging pharmaceutical manufacturer with direct distribution into U.S. generics markets
We maintain our AUD 1.25 fair value estimate for no-moat Mayne Pharma given the recent update by management on the U.S. generic industry trading environment. This follows the unprecedented level of price deflation in second-half fiscal 2017, which resulted in the disappointing performance of the U.S. generic products division and prompted our move to very high fair value uncertainty.Although acknowledging ongoing pressure, and reiterating soft first-half 2018 sales in the recent update, managem...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.